Indivior PLC (NASDAQ: INDV) Securities Fraud Class Action

LEAD PLAINTIFF DEADLINE IS OCTOBER 1, 2024.

If you have suffered losses and would like to discuss your rights, please fill out this form or you may contact Jonathan Naji, Esq. at (484) 270-1453 or via e-mail at info@ktmc.com.

Case Background:
On July 9, 2024, Indivior announced the company’s second quarter and full-year 2024 financial outlook and reduced: (1) total net revenue guidance to a range of $1.15 billion to $1.215 billion, from the previous range of $1.24 billion to $1.33 billion; (2) SUBLOCADE net revenue guidance to $765 million to $805 million from the previous range of $820 to $880 million (attributed primarily to accelerated Medicaid disenrollments at the end of the second quarter of 2024); and (3) OPVEE net revenue guidance to a range of $9 million to $14 million from the previous range of $15 million to $25 million (attributed to lagging adoption of OPVEE).  The company further announced it would immediately cease all sales and marketing activities related to PERSERIS due to the highly competitive market “and impending changes that are expected to intensify payor management in the treatment category in which PERSERIS participates.”  The company concluded that “there is no longer a path forward for PERSERIS that is financially viable.”  On this news, the price of Indivior common stock declined $5.15 per share, or approximately 33.57%, from a close of $15.34 per share on July 8, 2024, to close at $10.19 per share on July 9, 2024.

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects.  Specifically, Defendants misrepresented and/or failed to disclose that they: (1) grossly overstated their ability to forecast the negative impact of certain legislation related to Medicaid reimbursement rules on the financial prospects of Indivior products, which forecasting ability was far less capable and effective than they had led investors and analysts to believe; (2) overstated the financial prospects of SUBLOCADE, PERSERIS and OPVEE, and thus overstated the company’s anticipated revenue and other financial metrics; (3) knew or recklessly disregarded that, because of the negative impact of certain legislation on the financial prospects of Indivior’s products, Indivior was unlikely to meet its own previously-issued and repeatedly reaffirmed full-year 2024 net revenue guidance; and (4) knew or recklessly disregarded that Indivior was at a significant risk of, and/or was likely to, cease all sales and marketing activities related to PERSERIS.  As a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

What is a Lead Plaintiff?

A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case.  Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.